Emergent Biosolutions Company Profile (NYSE:EBS)

About Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions logoEmergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $1.54461 billion
  • Outstanding Shares: 41,211,000
Average Prices:
  • 50 Day Moving Avg: $36.27
  • 200 Day Moving Avg: $32.70
  • 52 Week Range: $24.47 - $38.74
P/E:
  • Trailing P/E Ratio: 23.96
  • Foreward P/E Ratio: 17.50
  • P/E Growth: 1.48
Sales & Book Value:
  • Annual Revenue: $512.21 million
  • Price / Sales: 3.03
  • Book Value: $15.10 per share
  • Price / Book: 2.49
Profitability:
  • EBIDTA: $159.99 million
  • Net Margins: 13.42%
  • Return on Equity: 14.50%
  • Return on Assets: 9.00%
Debt:
  • Debt-to-Equity Ratio: 0.40%
  • Current Ratio: 6.99%
  • Quick Ratio: 6.02%
Misc:
  • Average Volume: 285,075 shs.
  • Beta: 1.23
  • Short Ratio: 8.43
 

Frequently Asked Questions for Emergent Biosolutions (NYSE:EBS)

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions, Inc. (NYSE:EBS) posted its earnings results on Thursday, August, 3rd. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.26 by $0.13. The company earned $100.77 million during the quarter, compared to analysts' expectations of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. Emergent Biosolutions's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.05) EPS. View Emergent Biosolutions' Earnings History.

When will Emergent Biosolutions make its next earnings announcement?

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Emergent Biosolutions.

Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2017?

3 equities research analysts have issued 12-month price targets for Emergent Biosolutions' shares. Their forecasts range from $41.00 to $47.00. On average, they expect Emergent Biosolutions' stock price to reach $44.00 in the next year. View Analyst Ratings for Emergent Biosolutions.

What are analysts saying about Emergent Biosolutions stock?

Here are some recent quotes from research analysts about Emergent Biosolutions stock:

  • 1. According to Zacks Investment Research, "Emergent reported lower-than-expected earnings in the second-quarter of 2017, with revenue missing estimates. The company’s follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company. We are also positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it is expected to result in a reduced cost structure. On the flip side, the company’s sole dependence on BioThrax for its revenue is concerning. Meanwhile, Emergent faces competition from a number of companies with Biodefense products. Shares of the company have underperformed the broader industry so far this year. However, the U.S. government is the primary purchaser of BioThrax which is a big boost to the company." (8/11/2017)
  • 2. Cowen and Company analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)

Who are some of Emergent Biosolutions' key competitors?

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the folowing people:

  • Fuad El-Hibri, Executive Chairman of the Board
  • Daniel J. Abdun-Nabi, President, Chief Executive Officer, Director
  • Robert G. Kramer Sr., Chief Financial Officer, Executive Vice President, Administration, Treasurer
  • Adam Havey, Executive Vice President - Business Operations
  • Ronald B. Richard, Lead Independent Director
  • Sue Bailey M.D., Independent Director
  • Zsolt Harsanyi Ph.D., Independent Director
  • Jerome M. Hauer, Independent Director
  • George A. Joulwan USA, Independent Director

Who owns Emergent Biosolutions stock?

Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.67%), Dimensional Fund Advisors LP (5.38%), Aberdeen Asset Management PLC UK (4.24%), State Street Corp (3.34%), Acadian Asset Management LLC (3.02%) and Royal Bank of Canada (2.33%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Barry Labinger, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?

Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Acadian Asset Management LLC, Kennedy Capital Management Inc., State Street Corp, FIL Ltd, FMR LLC and GSA Capital Partners LLP. Company insiders that have sold Emergent Biosolutions stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Jerome M Hauer, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.

Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?

Emergent Biosolutions' stock was purchased by a variety of institutional investors in the last quarter, including Northern Trust Corp, Dimensional Fund Advisors LP, Rice Hall James & Associates LLC, Aberdeen Asset Management PLC UK, Renaissance Technologies LLC, New Amsterdam Partners LLC NY, Ameriprise Financial Inc. and Alliancebernstein L.P.. View Insider Buying and Selling for Emergent Biosolutions.

How do I buy Emergent Biosolutions stock?

Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of Emergent Biosolutions stock can currently be purchased for approximately $37.62.


MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Emergent Biosolutions (NYSE:EBS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $44.00 (16.96% upside)

Analysts' Ratings History for Emergent Biosolutions (NYSE:EBS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/30/2017Chardan CapitalReiterated RatingBuy$47.00N/AView Rating Details
1/9/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
10/1/2016Wells Fargo & CompanySet Price TargetBuy$41.00N/AView Rating Details
8/5/2016J P Morgan Chase & CoLower Price TargetOverweight$45.00 -> $36.00N/AView Rating Details
6/28/2016Singular ResearchLower Price TargetBuy$44.00 -> $40.00N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Emergent Biosolutions (NYSE:EBS)
Earnings by Quarter for Emergent Biosolutions (NYSE:EBS)
Earnings History by Quarter for Emergent Biosolutions (NYSE EBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017$0.41N/AView Earnings Details
8/3/2017Q2 2017$0.26$0.13$111.57 million$100.77 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.31$0.23$121.30 million$116.90 millionViewListenView Earnings Details
2/23/2017Q4 2016$0.48$0.74$120.45 million$151.66 millionViewListenView Earnings Details
11/7/2016Q3$0.26$0.58$112.30 million$142.91 millionViewListenView Earnings Details
8/4/2016Q2($0.17)($0.18)$111.20 million$101.49 millionViewListenView Earnings Details
5/5/2016Q1($0.07)$0.16$101.83 million$111.00 millionViewListenView Earnings Details
2/25/2016Q4$0.69$0.78$168.07 million$168.10 millionViewListenView Earnings Details
11/5/2015Q315$0.55$0.83$151.42 million$164.90 millionViewListenView Earnings Details
8/6/2015Q215$0.18$0.36$114.25 million$126.10 millionViewListenView Earnings Details
5/7/2015Q1($0.46)($0.50)$62.70 million$63.60 millionViewListenView Earnings Details
3/5/2015Q115$0.97$0.75$147.00 million$148.00 millionViewListenView Earnings Details
11/6/2014Q414$0.37$0.67$126.90 million$138.00 millionViewListenView Earnings Details
8/7/2014Q214$0.26$0.24$109.25 million$110.30 millionViewListenView Earnings Details
5/8/2014Q114($0.34)($0.40)$57.30 million$53.90 millionViewListenView Earnings Details
3/6/2014Q413$0.36$0.42$93.83 million$94.10 millionViewListenView Earnings Details
11/7/2013Q313$0.21$0.37$79.13 million$89.10 millionViewListenView Earnings Details
8/5/2013Q2 2013$0.21$0.29$75.73 million$82.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.14)($0.22)$46.17 million$43.10 millionViewListenView Earnings Details
3/7/2013Q4 2012$0.44$0.44$95.09 million$94.61 millionViewListenView Earnings Details
11/1/2012Q312$0.22$0.18$73.53 million$66.60 millionViewN/AView Earnings Details
8/2/2012$0.21$0.21ViewN/AView Earnings Details
5/3/2012($0.18)($0.19)ViewN/AView Earnings Details
3/8/2012$0.72$0.78ViewN/AView Earnings Details
11/3/2011($0.04)$0.04ViewN/AView Earnings Details
8/4/2011$0.33$0.40ViewN/AView Earnings Details
5/5/2011($0.52)($0.64)ViewN/AView Earnings Details
3/10/2011$0.67$0.76ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Emergent Biosolutions (NYSE:EBS)
Current Year EPS Consensus Estimate: $1.48 EPS
Next Year EPS Consensus Estimate: $2.15 EPS

Dividends

Dividend History for Emergent Biosolutions (NYSE:EBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Emergent Biosolutions (NYSE:EBS)
Insider Ownership Percentage: 16.50%
Institutional Ownership Percentage: 85.35%
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)
Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)
Insider Trades by Quarter for Emergent Biosolutions (NYSE:EBS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Fuad El-HibriChairmanSell25,000$38.50$962,500.00View SEC Filing  
9/8/2017Adam HaveyEVPSell7,885$37.06$292,218.10View SEC Filing  
9/7/2017Fuad El-HibriChairmanSell16,439$37.50$616,462.50View SEC Filing  
9/5/2017Fuad El-HibriChairmanSell3,100$37.50$116,250.00View SEC Filing  
8/31/2017Daniel Abdun-NabiCEOSell15,000$37.21$558,150.00View SEC Filing  
8/31/2017Fuad El-HibriChairmanSell5,461$37.50$204,787.50View SEC Filing  
8/15/2017Jerome M HauerDirectorSell10,776$35.83$386,104.08View SEC Filing  
7/27/2017Fuad El-HibriChairmanSell25,000$36.50$912,500.00View SEC Filing  
7/20/2017Fuad El-HibriChairmanSell25,000$35.50$887,500.00View SEC Filing  
4/3/2017Adam HaveyEVPSell11,419$28.62$326,811.78View SEC Filing  
3/8/2017Jerome M HauerDirectorSell2,576$31.27$80,551.52View SEC Filing  
1/17/2017Adam HaveyEVPSell8,438$29.75$251,030.50View SEC Filing  
1/17/2017Sue BaileyDirectorSell19,424$29.78$578,446.72View SEC Filing  
1/10/2017Daniel Abdun-NabiInsiderSell28,240$31.28$883,347.20View SEC Filing  
12/13/2016Ronald RichardDirectorSell5,900$34.09$201,131.00View SEC Filing  
6/6/2016George A JoulwanDirectorSell4,700$44.12$207,364.00View SEC Filing  
6/1/2016Daniel Abdun-NabiCEOSell8,699$43.74$380,494.26View SEC Filing  
5/27/2016Fuad El-HibriMajor ShareholderSell9,835$43.50$427,822.50View SEC Filing  
5/26/2016Fuad El-HibriMajor ShareholderSell39,759$43.13$1,714,805.67View SEC Filing  
5/25/2016Fuad El-HibriMajor ShareholderSell85,000$42.52$3,614,200.00View SEC Filing  
5/25/2016Zsolt HarsanyiDirectorSell27,867$42.33$1,179,610.11View SEC Filing  
5/24/2016Fuad El-HibriChairmanSell20,000$42.26$845,200.00View SEC Filing  
5/23/2016Fuad El-HibriChairmanSell45,000$42.62$1,917,900.00View SEC Filing  
5/20/2016Daniel Abdun-NabiCEOSell8,701$42.00$365,442.00View SEC Filing  
5/19/2016Jerome M HauerDirectorSell3,134$41.22$129,183.48View SEC Filing  
5/13/2016Louis W SullivanDirectorSell47,631$39.21$1,867,611.51View SEC Filing  
5/12/2016Fuad El-HibriMajor ShareholderSell25,000$38.71$967,750.00View SEC Filing  
5/12/2016Jerome M HauerDirectorSell4,700$38.50$180,950.00View SEC Filing  
5/11/2016Louis W SullivanDirectorSell9,969$39.25$391,283.25View SEC Filing  
4/22/2016Fuad El-HibriMajor ShareholderSell4,209$40.50$170,464.50View SEC Filing  
4/18/2016Daniel Abdun-NabiCEOSell8,702$40.17$349,559.34View SEC Filing  
4/18/2016Fuad El-HibriMajor ShareholderSell20,791$40.50$842,035.50View SEC Filing  
4/6/2016Fuad El-HibriMajor ShareholderSell50,000$39.00$1,950,000.00View SEC Filing  
4/6/2016Robert KramerEVPSell21,786$38.90$847,475.40View SEC Filing  
4/4/2016Robert KramerEVPSell21,788$36.90$803,977.20View SEC Filing  
4/1/2016Robert KramerEVPSell43,572$35.56$1,549,420.32View SEC Filing  
3/14/2016Adam HaveyEVPSell4,359$33.96$148,031.64View SEC Filing  
3/14/2016Jerome M HauerDirectorSell2,350$33.88$79,618.00View SEC Filing  
3/11/2016Adam HaveyEVPSell11,112$33.84$376,030.08View SEC Filing  
3/11/2016Louis W SullivanDirectorSell14,879$34.03$506,332.37View SEC Filing  
3/7/2016Marvin L WhiteDirectorSell33,134$35.42$1,173,606.28View SEC Filing  
1/4/2016Sue BaileyDirectorSell11,520$38.79$446,860.80View SEC Filing  
12/30/2015Ronald RichardDirectorSell21,600$40.00$864,000.00View SEC Filing  
12/24/2015Daniel Abdun-NabiCEOSell63,209$39.06$2,468,943.54View SEC Filing  
11/19/2015Fuad El-Hibrimajor shareholderSell17,871$37.50$670,162.50View SEC Filing  
11/13/2015Fuad El-Hibrimajor shareholderSell13,013$36.50$474,974.50View SEC Filing  
11/12/2015Barry LabingerEVPSell36,126$35.64$1,287,530.64View SEC Filing  
11/9/2015Fuad El-Hibrimajor shareholderSell13,225$35.50$469,487.50View SEC Filing  
11/6/2015Fuad El-Hibrimajor shareholderSell13,450$34.50$464,025.00View SEC Filing  
11/3/2015Fuad El-Hibrimajor shareholderSell13,689$33.50$458,581.50View SEC Filing  
9/11/2015Sue BaileyDirectorSell6,080$32.37$196,809.60View SEC Filing  
8/13/2015George A JoulwanDirectorSell7,200$34.72$249,984.00View SEC Filing  
7/20/2015Fuad El-HibriChairmanSell234$34.50$8,073.00View SEC Filing  
7/13/2015Ronald RichardDirectorSell4,922$34.00$167,348.00View SEC Filing  
6/29/2015Ronald RichardDirectorSell4,923$32.76$161,277.48View SEC Filing  
6/22/2015Fuad El-HibriMajor ShareholderSell74,564$32.60$2,430,786.40View SEC Filing  
6/16/2015Louis W SullivanDirectorSell13,457$31.33$421,607.81View SEC Filing  
6/15/2015Adam HaveyEVPSell36,298$31.55$1,145,201.90View SEC Filing  
6/15/2015Fuad El-HibriMajor ShareholderSell45,436$32.18$1,462,130.48View SEC Filing  
1/20/2015Fuad El-HibriMajor ShareholderSell15,325$27.67$424,042.75View SEC Filing  
12/26/2014Ronald RichardDirectorSell5,000$28.00$140,000.00View SEC Filing  
12/17/2014Ronald RichardDirectorSell5,000$27.00$135,000.00View SEC Filing  
12/11/2014Fuad El-HibriMajor ShareholderSell119,341$26.00$3,102,866.00View SEC Filing  
11/28/2014Fuad El-HibriMajor ShareholderSell34,577$25.00$864,425.00View SEC Filing  
11/25/2014Fuad El-HibriMajor ShareholderSell9,014$25.00$225,350.00View SEC Filing  
11/25/2014Zsolt HarsanyiDirectorSell8,000$24.82$198,560.00View SEC Filing  
11/12/2014Fuad El-HibriMajor ShareholderSell2,311$25.00$57,775.00View SEC Filing  
11/7/2014Robert KramerCFOSell2,625$24.00$63,000.00View SEC Filing  
4/16/2014Robert KramerCFOSell50,189$24.34$1,221,600.26View SEC Filing  
3/12/2014Adam HaveyEVPSell11,562$27.50$317,955.00View SEC Filing  
3/11/2014Adam HaveyEVPSell17,655$26.96$475,978.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Emergent Biosolutions (NYSE:EBS)
Latest Headlines for Emergent Biosolutions (NYSE:EBS)
Source:
DateHeadline
streetinsider.com logoEmergent BioSolutions (EBS) Secures $63M BARDA Contract to Develop Treatment for Cyanide Exposure - StreetInsider.com
www.streetinsider.com - September 20 at 4:16 AM
globenewswire.com logoEmergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure - GlobeNewswire (press release)
globenewswire.com - September 18 at 11:01 PM
streetinsider.com logoEmergent BioSolutions (EBS) Secures $63M BARDA Contract to Develop Treatment for Cyanide Exposure
www.streetinsider.com - September 18 at 5:59 PM
finance.yahoo.com logoEmergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure
finance.yahoo.com - September 18 at 5:59 PM
americanbankingnews.com logoEmergent Biosolutions (EBS) versus The Competition Head to Head Comparison
www.americanbankingnews.com - September 16 at 10:18 PM
americanbankingnews.com logoInsider Selling: Emergent Biosolutions, Inc. (EBS) Chairman Sells 25,000 Shares of Stock
www.americanbankingnews.com - September 14 at 10:52 PM
americanbankingnews.com logoAdam Havey Sells 7,885 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - September 12 at 4:14 PM
seekingalpha.com logoEmergent BioSolutions (EBS) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 8 at 6:34 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Chairman Fuad El-Hibri Sells 16,439 Shares
www.americanbankingnews.com - September 8 at 4:22 PM
americanbankingnews.com logoFuad El-Hibri Sells 3,100 Shares of Emergent Biosolutions, Inc. (EBS) Stock
www.americanbankingnews.com - September 6 at 8:52 PM
americanbankingnews.com logoInsider Selling: Emergent Biosolutions Inc (EBS) CEO Sells 15,000 Shares of Stock
www.americanbankingnews.com - September 5 at 7:46 PM
nasdaq.com logoEmergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It ... - Nasdaq
www.nasdaq.com - September 4 at 10:50 PM
finance.yahoo.com logoEmergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue? - Yahoo Finance
finance.yahoo.com - September 4 at 10:50 PM
finance.yahoo.com logoEmergent Biosolutions (EBS) Up 6% Since Earnings Report: Can It Continue?
finance.yahoo.com - September 4 at 5:47 PM
americanbankingnews.com logoInsider Selling: Emergent Biosolutions, Inc. (EBS) Chairman Sells 5,461 Shares of Stock
www.americanbankingnews.com - September 1 at 10:24 PM
americanbankingnews.com logoEmergent Biosolutions (EBS) versus Theravance Biopharma (TBPHV) Head to Head Contrast
www.americanbankingnews.com - August 29 at 12:10 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - August 25 at 9:44 PM
finance.yahoo.com logoETFs with exposure to Emergent BioSolutions, Inc. : August 23, 2017
finance.yahoo.com - August 23 at 8:24 PM
nasdaq.com logoCVS Health (CVS) Releases Encouraging Flu Shot Survey Data - Nasdaq
www.nasdaq.com - August 22 at 3:46 AM
americanbankingnews.com logoInsider Selling: Emergent Biosolutions, Inc. (EBS) Director Sells 10,776 Shares of Stock
www.americanbankingnews.com - August 17 at 7:58 PM
finance.yahoo.com logoBiotech movers: Ionis Drops After GSK Bows Out of Partnership
finance.yahoo.com - August 11 at 6:34 PM
americanbankingnews.com logoEmergent Biosolutions Inc (NYSE:EBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 11 at 2:15 PM
finance.yahoo.com logoEmergent BioSolutions, Inc. :EBS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 7:23 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
finance.yahoo.com - August 9 at 11:18 PM
fool.com logoEmergent Biosolutions Inc Diversifies Its Revenue
www.fool.com - August 7 at 3:53 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - August 6 at 11:56 AM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Releases Earnings Results, Misses Expectations By $0.13 EPS
www.americanbankingnews.com - August 5 at 5:32 PM
nasdaq.com logoEmergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - August 5 at 4:25 AM
finance.yahoo.com logoEdited Transcript of EBS earnings conference call or presentation 3-Aug-17 9:00pm GMT
finance.yahoo.com - August 4 at 6:21 PM
finance.yahoo.com logoErste CEO on Earnings, Czech Housing Market, Brexit
finance.yahoo.com - August 4 at 6:21 PM
finance.yahoo.com logoEmergent Biosolutions misses 2Q profit forecasts
finance.yahoo.com - August 4 at 6:21 PM
finance.yahoo.com logoEmergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
finance.yahoo.com - August 4 at 6:21 PM
finance.yahoo.com logoInvestor Network: Emergent BioSolutions Inc. to Host Earnings Call
finance.yahoo.com - August 3 at 5:07 PM
finance.yahoo.com logoEmergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance
finance.yahoo.com - August 3 at 5:07 PM
finance.yahoo.com logoETFs with exposure to Emergent BioSolutions, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 6:46 PM
finance.yahoo.com logoEmergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense
finance.yahoo.com - July 31 at 5:53 PM
americanbankingnews.com logoFuad El-Hibri Sells 25,000 Shares of Emergent Biosolutions, Inc. (NYSE:EBS) Stock
www.americanbankingnews.com - July 28 at 4:32 PM
streetinsider.com logoEmergent BioSolutions (EBS) Secures Licensing Agreement with Valneva SE for Worldwide Exclusive Rights to Zika Vaccine Technology
www.streetinsider.com - July 27 at 12:16 AM
streetinsider.com logoEmergent BioSolutions (EBS) Secures Licensing Agreement with Valneva SE for Worldwide Exclusive Rights to Zika ... - StreetInsider.com
www.streetinsider.com - July 26 at 6:41 PM
finance.yahoo.com logoEmergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology
finance.yahoo.com - July 26 at 6:41 PM
finance.yahoo.com logoVALNEVA and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus
finance.yahoo.com - July 26 at 6:40 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri Sells 25,000 Shares
www.americanbankingnews.com - July 21 at 7:28 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (NYSE:EBS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 21 at 11:42 AM
globenewswire.com logoEmergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 3:25 PM
finance.yahoo.com logoEmergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
finance.yahoo.com - July 20 at 3:25 PM
finance.yahoo.com logoEmergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
finance.yahoo.com - July 19 at 9:18 PM
zacks.com logoEmergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
www.zacks.com - July 17 at 7:01 PM
finance.yahoo.com logoEmergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
finance.yahoo.com - July 17 at 7:01 PM
americanbankingnews.com logoEmergent Biosolutions, Inc. (EBS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:26 PM
rttnews.com logoEmergent BioSolutions To Buy ACAM2000 Business From Sanofi For Up To $125 Mln
www.rttnews.com - July 16 at 5:28 PM

Social

Chart

Emergent Biosolutions (EBS) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff